echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > JCC: Effects of biologic therapy on the probability of AD patients being positive for SARS-CoV2

    JCC: Effects of biologic therapy on the probability of AD patients being positive for SARS-CoV2

    • Last Update: 2020-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Background and targets are reported to have similar course of COVID-19 in patients with inflammatory bowel disease (IBD) and in the general population.
    , however, it is not clear how likely IBD patients are to develop new coronary pneumonia.
    this prospective observational study, the researchers aimed to determine the rate of SARS-CoV2 infection in IBD patients treated with biotherapy.
    method researchers evaluated the presence of antibodies in 354 serums from IBD patients receiving biological treatment in three different regions of Italy and Germany.
    control groups were: i) healthy subjects who were age-matched at the same time in Milan, Italy;
    354 patients tested positive for SARS-CoV2 IgG antibodies (prevalence 2.3%).
    percentage of IgG-positive patients recruited from Milan is significantly higher than that of IgG patients recruited from other regions (prevalence rate 5.4% VS 0.4%, p -lt;0.005).
    IgG-positive patients reported significantly higher rates of fever, insomnia and hearing abnormalities, and were more likely to have close contact with COVID-19-positive subjects before participating in the study.
    that the SARS-CoV2 serotony positive in IBD patients treated with biotherapy reflected measurements from the local general population.
    specific symptoms and history of exposure associated with SARS-CoV2 strongly increased the likelihood of SARS-CoV2 sero-positive.
    biologics are not a risk factor for infection with the new crown in IBD patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.